These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 11004222

  • 1. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
    Tran HTB, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H, Kirkman RL, Milford EL.
    J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
    [Abstract] [Full Text] [Related]

  • 2. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J, Arns W, Marti HP, Hauss J, Ketteler M, Beckurts T, Boesmueller C, Pohanka E, Martin PY, Gerhardt M, Farese S, Neumayer HH, Floege J, Gurr C, Budde K, DACH Study Group.
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F.
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [Abstract] [Full Text] [Related]

  • 4. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 5. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
    Ekberg H, Persson NH, Källen R, Gül-Baykurt N.
    Scand J Immunol; 2003 Dec 15; 58(6):670-7. PubMed ID: 14636424
    [Abstract] [Full Text] [Related]

  • 6. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun 15; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 7. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2005 May 15; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [Abstract] [Full Text] [Related]

  • 8. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 9. The effect of Daclizumab in a high-risk renal transplant population.
    Meier-Kriesche HU, Kaza H, Palekar SS, Friedman GS, Mulgaonkar SP, Ojo AO, Kaplan B.
    Clin Transplant; 2000 Oct 27; 14(5):509-13. PubMed ID: 11048998
    [Abstract] [Full Text] [Related]

  • 10. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.
    Nephrol Dial Transplant; 2008 Jun 27; 23(6):2024-32. PubMed ID: 18199693
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 12. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.
    Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW.
    J Am Soc Nephrol; 2002 Feb 27; 13(2):536-543. PubMed ID: 11805185
    [Abstract] [Full Text] [Related]

  • 13. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb 27; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
    Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M.
    Am J Transplant; 2007 Mar 27; 7(3):560-70. PubMed ID: 17229079
    [Abstract] [Full Text] [Related]

  • 15. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 16. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 17. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Transplant; 2003 Jun 15; 17(3):234-41. PubMed ID: 12780674
    [Abstract] [Full Text] [Related]

  • 18. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
    Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P, Cyclosporine Withdrawal Study Group.
    J Am Soc Nephrol; 2005 Jul 15; 16(7):2234-40. PubMed ID: 15917338
    [Abstract] [Full Text] [Related]

  • 19. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 15; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

  • 20. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.
    Sheashaa HA, Bakr MA, Fouda MA, El-Dahshan KF, Ismail AM, Sobh MA, Ghoneim MA.
    Int Urol Nephrol; 2007 Aug 15; 39(1):317-9. PubMed ID: 17333530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.